|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Mirati Therapeutics, Inc. (MRTX) |
|
|
$58.70 0.00 (0.00%) as of 4:30 Mon 1/22
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
83,668,000 |
| Market
Cap: |
4.91(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$27.8 - $62.38 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. Co.'s KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. Co. also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. Co.'s clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. Co. has several discovery programs, including a preclinical program for a KRAS G12D inhibitor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,269,764 |
1,269,764 |
| Total Buy Value |
$0 |
$0 |
$35,299,439 |
$35,299,439 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
0 |
11,422 |
19,076 |
136,645 |
| Total Sell Value |
$0 |
$664,751 |
$950,088 |
$10,440,645 |
| Total People Sold |
0 |
2 |
3 |
7 |
| Total Sell Transactions |
0 |
6 |
9 |
23 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cherrington Julie M |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
11,252 |
|
- |
|
| Davis Aaron I. |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
54,325 |
|
- |
|
| Christensen Jamie |
EVP & Chief Scientific Officer |
• – – |
2023-12-29 |
4 |
A |
$58.75 |
$999,984 |
D/D |
17,021 |
158,666 |
|
- |
|
| Hasnain Faheem |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$569,993 |
D/D |
9,702 |
24,752 |
|
- |
|
| Ondrey Aaron |
CFO |
• – – |
2023-12-29 |
4 |
A |
$58.75 |
$999,984 |
D/D |
17,021 |
39,461 |
|
- |
|
| Baum Charles M |
Interim CEO |
• • – |
2023-12-29 |
4 |
A |
$58.75 |
$1,199,969 |
D/D |
20,425 |
247,700 |
|
- |
|
| Martinez Maria E |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
17,273 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
16,222 |
|
- |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2023-12-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,396,979 |
|
2% |
|
| Christensen Jamie |
EVP & Chief Scientific Officer |
• – – |
2023-12-18 |
4 |
S |
$57.50 |
$137,253 |
D/D |
(2,387) |
141,645 |
|
-2% |
|
| Hickey Benjamin |
EVP, Chief Commercial Officer |
• – – |
2023-12-13 |
4 |
S |
$56.67 |
$125,807 |
D/D |
(2,220) |
103,694 |
|
-2% |
|
| Ondrey Aaron |
Interim CFOOfficer |
• – – |
2023-09-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,028 |
|
65% |
|
| Christensen Jamie |
EVP & Chief Scientific Officer |
• – – |
2023-09-08 |
4 |
S |
$35.63 |
$85,084 |
D/D |
(2,388) |
144,032 |
|
-65% |
|
| Ondrey Aaron |
Interim CFO |
• – – |
2023-09-08 |
4 |
A |
$35.66 |
$299,972 |
D/D |
8,412 |
22,440 |
|
- |
|
| Fuglesang Christopher |
See remarks |
• • – |
2023-08-11 |
4 |
B |
$27.80 |
$33,400,032 |
D/D |
1,201,440 |
3,201,440 |
0.01 |
51% |
|
| Fuglesang Christopher |
See remarks |
• • – |
2023-08-11 |
4 |
B |
$27.80 |
$1,599,417 |
I/I |
57,533 |
287,866 |
0.01 |
51% |
|
| Hasnain Faheem |
Director |
– • – |
2023-08-11 |
4 |
B |
$27.80 |
$299,990 |
I/I |
10,791 |
10,791 |
2.1 |
51% |
|
| Baum Charles M |
Interim CEO |
• • – |
2023-08-09 |
4 |
A |
$37.00 |
$1,999,998 |
D/D |
54,054 |
227,275 |
|
- |
|
| Moriarty John B |
Chief Legal Officer |
• – – |
2023-08-09 |
4 |
A |
$37.00 |
$824,989 |
D/D |
22,297 |
71,660 |
|
- |
|
| Hickey Benjamin |
EVP, Chief Commercial Officer |
• – – |
2023-08-09 |
4 |
A |
$37.00 |
$824,989 |
D/D |
22,297 |
105,914 |
|
- |
|
| Stelzer Laurie |
Chief Financial Officer |
• – – |
2023-08-09 |
4 |
A |
$37.00 |
$824,989 |
D/D |
22,297 |
102,312 |
|
- |
|
| Sandler Alan B. |
Chief Medical Officer |
• – – |
2023-08-09 |
4 |
A |
$37.00 |
$824,989 |
D/D |
22,297 |
62,297 |
|
- |
|
| Christensen Jamie |
EVP & Chief Scientific Officer |
• – – |
2023-08-09 |
4 |
A |
$37.00 |
$824,989 |
D/D |
22,297 |
146,420 |
|
- |
|
| Moriarty John B |
Chief Legal OfficerOfficer |
• – – |
2023-06-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
49,363 |
|
49% |
|
| Gallagher Carol Giltner |
Director |
– • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,555 |
7,555 |
|
- |
|
370 Records found
|
|
Page 2 of 15 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
